ELIQUIS is the # 1 most prescribed oral anticoagulant among cardiologists for new patient starts * Explore the efﬁ cacy and safety data hcp.eliquis.com * Based on IMS SDI VECTOR New-to-brand Prescription Database (NBRx). Oral anticoagulant prescriptions were written by cardiologists and ﬁ lled by patients who did not have any prescriptions ﬁ lled for that same oral anticoagulant in the previous 6 months. Claims valid as of 1/3/14 to 8/12/16. INDICATIONS ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial ﬁ brillation. ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy. SELECTED IMPORTANT SAFETY INFORMATION WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. Please see additional Important Safety Information, including continued Boxed WARNINGS, on adjacent page.